{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-142911","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2026-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.347838+00:00","generated_at":"2026-05-15T07:16:48.460082+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Neurocrine to acquire Soleno for $53.00/share in $2.9B all-cash transaction","bullets":["Deal price $53.00 per share; total equity value ~$2.9B; Soleno board recommends shareholders tender.","VYKAT XR generated $190M revenue in 2025, including $92M in Q4 2025; IP expected to extend to mid-2040s.","Conditions include tender of >50% of shares, HSR clearance, no material adverse effect, and customary representations.","Termination fee: $95.25M from Soleno under certain circumstances; $141.5M from Neurocrine if antitrust blocks deal.","Principal stockholders holding ~1.01% of shares have agreed to tender and vote in favor via support agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-142911","json":"https://secwatch.observer/filing/0001193125-26-142911.json","markdown":"https://secwatch.observer/filing/0001193125-26-142911.md","text":"https://secwatch.observer/filing/0001193125-26-142911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526142911/0001193125-26-142911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526142911/d142985d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:16:48.460082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0d1c4cb013d74e390448d0ffdcb75dd04ebc317","claim":"SOLENO THERAPEUTICS INC entered into Agreement and Plan of Merger with Neurocrine Biosciences, Inc. valued at $53.00 per share cash tender offer for all outstanding common stock; merger consideration of $53.00 (effective 2026-04-05).","evidence_excerpt":"Item 1.01 Entry Into a Material Definitive Agreement. Agreement and Plan of Merger On April 5, 2026, Soleno Therapeutics, Inc. a Delaware corporation (the “Company” or “Soleno”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Neurocrine Biosciences, Inc., a Delaware corporation (“Parent”), and Sigma Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), pursuant to which Parent, through Purchaser, will commence a cash tender offer (the “Offer”) to purchase all of the issued outstanding shares of the common stock, par value $0.001 (the “Shares”), of the Company, at a price per share of $53.00 per share (the “Offer Price”) in cash, without interest, subject to any applicable withholding taxes.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526142911/0001193125-26-142911-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Neurocrine Biosciences, Inc."},{"label":"Value","value":"$53.00 per share cash tender offer for all outstanding common stock; merger consideration of $53.00"},{"label":"Effective","value":"2026-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}